Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis.

ABSTRACT:

Background

Antipsychotics are the gold standard treatment for schizophrenia, but many patients who receive treatment experience persistent symptoms. The aim of this network meta-analysis was to determine the efficacy of augmentation drugs for the treatment of schizophrenia.

Methods

In accordance with the PRISMA statement, the PubMed, Web of Science, Google Scholar, CENTRAL, clinical trial and EUDRACT databases were searched from inception to May 15th, 2023. To ensure the robustness of the results, only double-blind randomised controlled trials with a low risk of bias (measured by the Risk Of Bias v2 (ROB2) tool) were included. The studies were categorised according to the background regimen: participants were treated with risperidone, mixed antipsychotics or clozapine. A Bay

SUBMITTER: Etchecopar-Etchart D 

PROVIDER: S-EPMC10864200 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature